Adaptive (ADPT) Q2 Revenue Surges 36%
Adaptive Biotechnologies (NASDAQ:ADPT), a company specializing in immune-driven clinical diagnostics and therapeutics, posted its second quarter fiscal 2025 earnings on August 5, 2025. The report revealed a significant jump in revenue to $58.9 million (GAAP), beating analyst expectations of $49.4 million (GAAP) by a wide margin. Most revenue growth stemmed from the company’s minimal residual disease (MRD) molecular testing business, which reached positive Adjusted EBITDA for the first time. Despite ongoing net losses, the company made marked improvements across core metrics, revising full-year 2025 MRD revenue guidance higher and forecasting reduced cash burn, with full year 2025 company cash burn guidance updated to a range of $45 million to $55 million. The company demonstrated accelerating operational momentum and concrete progress toward profitability.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Adaptive Biotechnologies operates at the intersection of biotechnology and clinical diagnostics, with a focus on decoding the adaptive immune system. Its business centers on two main areas: Minimal Residual Disease (MRD) testing, largely through its clonoSEQ molecular diagnostic test, and the Immune Medicine segment, which applies immune profiling to research and therapy development.
Source Fool.com
